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ABSTRACT 
Objective: To characterize the effects of granulocyte colony- 
stimulating factor (G-C%) or granulocyte-macrophage colony- 
stimulating factor (GM-C%) on clinical outcomes in neutropenic 
HIV-infected patients, by means of a retrospective cohort study 
at an urban teaching hospital. 
Method: Data were reviewed from all patients discharged 
between January 1, 1996, and August 31, 1997, with human 
immunodeficiency virus and neutropenia (absolute neutrophil 
count (ANC) <I 000 cells/pL), with outcome measures of length 
of stay, infectious complications, and survival to discharge. 
Results: Of the 228 discharged patients who met selection cri- 
teria, 71 had received G-CSF or GM-CSF; 157 controls had 
not. Cases had lower CD4+ cell counts (30 vs. 54 cells/pL; 
P = 0.017) and lower nadir ANCs (372 vs. 579 cells/pL; 
P < 0.001). Granulocyte-CSF or GM-CSF usage was not asso- 
ciated with the frequency of site-related infections, fever, or 
sepsis (all P > 0.20). No difference was found in duration of hos- 
pitalization (23 vs. 21 days; P > 0.20). In a logistic regression 
model for survival to discharge, higher nadir ANC and CSF use 
were independently associated with improved survival 
(P = 0.034 and P = 0.026, respectively). 
Conclusion: Use of G-CSF or GM-CSF was associated with 
improved survival to discharge among hospitalized HIV-infected 
patients with neutropenia. 
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Neutropenia frequently complicates human immunodefi- 
ciency virus (HIV) infection and acquired immunodefi- 
ciency syndrome (AIDS), with up to a 40% prevalence of 
low absolute neutrophil counts (ANCs) reported.’ Causes 
of HIV-related neutropenia include myelophthisic 
processes, HIV-induced autoimmune abnormalities, 
chemotherapy against HIV-related malignancies, and use 
of antimicrobials against HIV and opportunistic infections. 
Whereas neutropenia is a risk factor for bacterial infection 
in cancer patients, 2,3 the risk contribution of neutropenia 
for infectious complications in HIV has been unclear.4-9 
Granulocyte colony-stimulating factor (G-CSF) and 
granulocyte-macrophage colony-stimulating factor (GM- 
CSF) have been used to lessen the severity and duration 
of neutropenia due to chemotherapy. I0 These agents have 
not been shown to reduce mortality or hospital stay in 
patients with febrile neutropenia,l’-l5 and are not rou- 
tinely recommended in chemotherapy-related febrile neu- 
tropenia, according to the guidelines of American Society 
of Clinical Oncology. 16,17 Their use in HIV disease is less 
well-studied. Granulocyte-CSF and GM-CSF (CSFs) have 
been shown to be safe and effective as adjuncts, allow- 
ing full-dose administration of ganciclovir.18-20 Recently, 
reports have found G-CSF, when used in an oupatient set- 
ting to keep the ANC over 500 cells/pL, reduces the fre- 
quency of bacteremia in HIV-infected individuals and 
improves surviva1.21,22 
To determine whether CSF use affects clinical out- 
comes among hospitalized, neutropenic HIV-infected 
patients, the authors conducted a retrospective review 
of inpatients with HIV and neutropenia at an urban teach- 
ing hospital in NewYork. The primary aims were to quan- 
tity the effects of CSFs on survival to discharge, length of 
stay, and frequency of infectious episodes. 
MATERIAL AND METHODS 
Study Characteristics and Patients 
This was a retrospective cohort study of HIV-seroposi- 
tive inpatients at the Beth Israel Medical Center in New 
York, an SOO-bed urban university teaching hospital and 
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tertiary care center. Selection criteria included a diagno- 
sis of HTV and an ANC of less than 1000 cells/FL during 
hospital course. Patient confidentiality was preserved by 
assigning study-specific identifiers and using only these 
identifiers in the study’s database. Eligible patients were 
identified from the hospital database of all discharge diag- 
noses. International Classification of Diseases (ICD, 9th 
Revision, Department of Health and Human Services, US 
Government Printing Office, Washington, DC, 1997) codes 
used were those for agranulocytosis, neutropenia, and 
pancytopenia (288.0 and 284.8) and any AIDS-related 
diagnosis code (including 042 and VO8 for AIDS and HIV 
as well as codes for any AIDSdefining opportunistic infec- 
tions), for the period from January 1,1996, to August 3 1, 
1997. The occurrence of an ANC less than 1000 cells&L 
was confirmed by review of laboratory data. 
The records of all patients who met selection crite- 
ria were reviewed by one of the authors (BRA). Data on 
patient demographics, clinical history and hospital course 
were collected on a standardized data collection instru- 
ment. Patient demographics recorded included date of 
birth, race or ethnic&y, gender, age, history of injection 
drug use (IDU), admission and discharge dates, and date 
of neutropenia onset. 
Clinical history abstracted included the most recent 
CD4+ cell count, myelosuppressive chemotherapy use 
within 1 month of neutropenia onset, presence of cen- 
tral venous catheter, use of myelosuppressive antimicro- 
bial agents (trimethoprim-sulfamethoxazole, ganciclovir, 
zidovudine, amphotericin, pyrimethamine, sulfadiazine, 
and pentamidine) within 1 week of neutropenia onset, 
and documented Mycobacterium avium complex (MAC) 
or biopsy-documented bone marrow infiltration by tuber- 
culosis, lymphoma, or histoplasmosis. 
Records were reviewed to obtain information on 
nadir ANC, duration of neutropenia (at 3 strata of <lo00 
cells&L, ~500 cells&L, and ~200 cells/FL), the number 
of neutropenic episodes, and the development of infec- 
tious complications during neutropenia. In all cases, com- 
plete blood counts (CBCs) were performed at least every 
other day while patients were neutropenic. A neutropenic 
episode was considered distinct if there were at least 7 
non-neutropenic days between days of neutropenia.23 
Infectious complications included fever (defined as an 
oral or rectal temperature of >38”C), sepsis (defined as 
systolic blood pressure <90 mmHg, organ dysfunction, 
lactic acidosis, oliguria, or altered mental status in the set- 
ting of presumed infection), development of bacteremia 
or fungemia (defined as a recognized pathogen on blood 
cultures), and of site-related infections (e.g., endocardi- 
tis, pneumonia, meningitis, enterocolitis, cellulitis, intra- 
abdominal infections, catheter-related infections, and 
urinary tract infections). Infectious complications were 
required to meet the National Institute of Allergy and 
Infectious Diseases’ clinical endpoint definitions.‘* Out- 
comes were survival to discharge and length of stay 
Granulocyte Colony-Stimulating Factor and 
Granulocyte-Macrophage Colony-Stimulating 
Factor Use 
Standard doses of G-CSF and GM-CSF were 300 kg and 
250 Fg, respectively, given via subcutaneous injection. 
Colony-stimulating factor dosing was analyzed with 
respect to frequency (daily vs. 3 times/wk), duration of 
use, and days of neutropenia within each stratum prior 
to initiation of therapy. Delay in administration of G-CSF 
or GM-CSF was defined as 1 or more days of neutrope- 
nia prior to CSF initiation. 
Statistical Analyses 
Statistical analysis was performed with the Statistics Pack- 
age for Social Sciences (SPSS for Windows’“6.0.1, SPSS 
Inc., NewYork). Infectious complications and duration of 
neutropenia were analyzed by neutropenic episodes, and 
length of stay and survival to discharge were analyzed by 
admissions. Independent sample t-tests were used to com- 
pare continuous variables, and chi-square tests were used 
to compare noncontinuous variables. Logistic regression 
was used when two or more variables were associated 
with each other and a dichotomous variable. Pearson’s 
and partial correlations were used to determine associa- 
tions among continuous variables. 
RESULTS 
Population Derivation 
Between January 1,1996, and August 3 1,1997,640 admis- 
sions from 478 patients with discharge diagnoses of neu- 
tropenia and an AIDS-related disorder were identified. 
For 398 discharges, there was no documented ANC less 
than 1000 cells/uL. Among 168 patients, 242 admissions 
were found to meet study criteria. Fourteen admissions 
were excluded owing to incomplete records, leaving 228 
evaluable admissions (among 163 patients). Of these, 71 
admissions (cases) among 51 patients received CSFs (51 
G-CSF; 20 GM-0 and 157 admissions (controls) among 
112 patients did not. 
Of the 228 admissions, 13 (representing 11 patients) 
involved more than one neutropenic episode per admis- 
sion (33 episodes in these admissions). Six of these 
patients (total of 17 episodes) received CSFs in one or 
more episodes and did not in other episodes during the 
same admission. These six (of whom 3 died) were 
excluded from analyses of CSF effects on length of stay 
and survival analyses. 
Baseline Characteristics 
Cases had significantly more admissions than controls 
(1.7 vs. 1.3, P = 0.02). Baseline characteristics are shown 
in Table 1. Cases more frequently had a history of injec- 
tion drug use (IDU), had received myelosuppressive 
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Table 1. Case Characteristics 
Cases 
Receiving Controls 
CSF (n = 71) (n = 157) P* 
Age (y) (mean + SD) 39t11 40 k 9 
Sex (%) 
Male 50 (71) 114 (73) 
Female 21 (29) 43 (27) 
Race (“Y) 
White 19 (27) 27 (17) 
Black 24 (34) 64 (41) 
Hispanic 24 (34) 63 (40) 
Asian 3 (5) 3 (2) 
IDU history (%) 21 (31) 77 (51) 0.006 
CD4+ (mean ? SD) 30 k 58 54 2 85 0.017 
Nadir ANC (mean ? SD) 372 t 227 579 -c 242 <O.OOl 
Recent chemotherapy (%) 14 (20) 2 (1) <O.OOl 
Marrow infiltrative disorder (%) 35 (49) 58 (37) 
MAC 35 53 0.034 
Histoplasmosis 0 2 
Tuberculosis 0 3 
Lymphoma 
Antimicrobial therapy (%) 59 p83) 
1 
129 (82) 
Cotrimaxozole 44 107 
Ganciclovir 27 22 <O.OOl 
Zidovudine 19 47 
Pyrimethamine 7 6 
Sulfadiazine 5 6 
Intravenous pentamidine 4 6 
Intravenous amphotericin 5 14 
Other 8 
Central venous catheter (%) 30 (343) 35 (22) 0.002 
*Only significant P-values (by chi-square analysis) are shown. IDU = injection 
drug use: ANC = absolute neutrophil count, MAC = M. avium complex. 
chemotherapy within the previous month, had received 
ganciclovir within 1 week of neutropenia onset, had a 
central venous catheter, and had MAC infection. Patients 
undergoing chemotherapy had a lower nadir ANC (234 
vs. 538 cells/FL; P < 0.001). No other significant relation 
among baseline characteristic was found (all P > 0.10). 
Colony-Stimulating Factor Use 
In 16 cases, CSFs were administered three times per week 
instead of daily. In 37 cases, CSF administration was 
delayed, with a median delay of 3 days. Patients who had 
a lower nadir ANC had longer delays in administration 
(J? = 0.03). These differences in dosing regimens were 
not associated with any differences in baseline charac- 
teristics or outcomes. Colony-stimulating factors were 
continued until recovery from neutropenia, death, or 
discharge. 
Factors Affecting Duration of Neutropenia 
The severity of neutropenia (i.e., lower nadir ANC) was 
associated with the duration of neutropenia at each stra- 
tum (days below ANC of 1000 cells/FL, 500 cells/pL, 200 
cells/FL; all P < 0.001). No other baseline characteristics 
were associated with duration of neutropenia at any stra- 
tum (all P > 0.1). Although there was a trend toward 
cases having a longer duration of neutropenia than con- 
trols (8 d vs. 6 d; P = 0.06), this did not persist when neu- 
tropenic episodes with delayed CSF administration were 
excluded (all P > 0.1). 
Factors Affecting Infectious Complications 
Table 2 shows the infectious complications in cases and 
controls. Cases more frequently developed fever, bac- 
teremia, and sepsis. Cases had a higher rate of site-related 
infections due to more frequent catheter infections. After 
excluding those with delayed CSF administration (to 
exclude cases where infectious complications may have 
prompted CSF use) or catheter infections, there was no 
significant difference in rates of site-related infections 
(30% vs. 21%; P > 0.2), fever (49% vs. 48%; P > 0.9), or sep- 
sis (30% vs. 19%; P = 0.13). However, cases still had a 
higher likelihood of bacteremia [odds ratio (OR) = 7.7; 
95% confidence interval (CI) = 1.8-33.9; P = 0.0021. 
Mycobacterium avium complex infection was sig- 
nificantly associated with the development of bacteremia 
(OR = 4.0; 95% CI = 1.5-10.2; P = 0.002). The presence 
of a central venous catheter was significantly associated 
with the rate of bacteremia (OR = 5.9; 95% CI = 2.3-14.6; 
P < 0.001) and site-related infections (OR = 2.8; 95% CI 
=1.5-5.3; P = O.OOl).The duration of neutropenia at any 
stratum, CD4+ cell count, and nadir ANC were not asso- 
ciated with the development of bacteremia or site-related 
infections (all P > 0.10). 
Patients developing sepsis had longer neutropenic 
periods below an ANC of 500 cells/p,L (3 vs. 2 d; 
P = 0.04), and a lower nadir ANC (398 vs. 550 cells/p,L; 
P i 0.001). Patients undergoing chemotherapy more fre- 
quently developed sepsis [S/16 (50%) vs. 45/212 (21%); 
Table 2. Infectious Complications 
Cases 
Receiving Contra/s 
CSF(n= 71) (n = 157) P 
Fever (%) 46 (66) 76 (48) 0.016 
Sepsis (%) 24 (34) 29 (19) 0.009 
Blood-borne (%) 14 (20) 6 (5) <O.OOl 
Staphylococcus aureus 6 4 
Pseudomonas 3 1 
Enterobacter 0 1 
Enterococcus 2 4 
Klebsiella 2 2 
Staphylococcus epidermidis 2 0 
Fungus 
Site-Related Infections 24 :34) 33 h:, 0.033 
Endocarditis 1 1 
Pneumonia 6 11 
Meningitis 1 3 
Enterocolitis 0 3 
Intra-abdominal infection 2 3 
Urinary tract infection 2 5 
Catheter-related infection 11 6 0.002 
Skin/wound infection 3 3 
Pericarditis 0 1 
Pelvic inflammatory disease 0 1 
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P = 0.004]. No other baseline characteristic was associ- 
ated with any infectious complication (all P > 0.10). 
Factors Affecting Length of Stay 
For the study population, the median length of stay was 
22 days. No significant difference existed between cases 
and controls (23 vs. 21 d; P = 0.38). Patients developing 
infectious complications had longer lengths of stay (25 
vs. 20 d; P = 0.04). No baseline characteristics were asso- 
ciated with length of stay (all P > 0.10). 
Factors Affecting Survival 
There was no difference in overall survival to discharge 
between cases and controls [55/65 (85%) vs. 130/157 
(83%); P > 0.71. Among those with a nadir ANC of 251 
to 500 cells/p,L, cases had a higher rate of survival than 
controls [22/23 (96%) vs. 31/40 (78%); P = 0.031. There 
was a trend toward improved survival among septic 
patients receiving CSFs [15/24 (63%) vs. 11/29 (38%); 
P = 0.0751, whereas nonseptic patients had similar sur- 
vival rates [cases: 42/45 (93%); controls: 121/128 (95%); 
P > 0.81. Survival of septic patients with a nadir ANC of 
25 1 to 500 cells/pL was significantly associated with CSF 
use [6/6 (100%) vs. 2/S (25%); P = 0.0051. 
Patients surviving to discharge had lower rates of 
bacteremia [ 13/189 (7%) vs. lo/39 (26%); P < 0.0011, site- 
related infection [39/189 (21%) vs. 18/39 (46%); 
P < O.OOl], fever [94/189 (50%) vs. 28/39 (72%); 
P = 0.004], and sepsis [26/189 (14%) vs. 27/39 (69%); 
P < O.OOl]. They had shorter lengths of stay (19 + 13 vs. 
35 t 32, P = 0.002) and a higher nadir ANC (540 t 251 
vs. 403 ? 246; P = 0.003). Patients who survived had no 
significant differences from those who did not in dura- 
tion of neutropenia at any stratum (all P > 0.10). No other 
baseline characteristic was associated with survival (all 
P > 0.10). 
Multivariate Analyses 
All variables having a univariate P-value of <O.lO with 
bacteremia, sepsis, and survival were tested for inter- 
actions in logistic regression models. 
Independent predictors of bacteremia included CSF 
administration (adjusted OR = 3.2; 95% CI = 1.2-8.5; 
P = 0.02), MAC infection (adjusted OR = 2.7; 95% 
CI = 1.0-7.4; P = 0.05) and the presence of a central 
venous catheter (adjusted OR = 4.6; 95% CI = 1.7-12.3; 
P = 0.003). After excluding patients with catheter infec- 
tions, CSF use was significantly associated with the devel- 
opment of bacteremia (adjusted OR = 6.1; 95% 
CI = 1.5-25.0; P = 0.01) but MAC infection and the pres- 
ence of a central venous catheter were not (P = 0.17 and 
P = 0.99, respectively). 
Patients with less severe neutropenia had decreased 
risk (for each increase in nadir ANC by 100 cells/p,L, 
adjusted OR = 0.8; 95% CI = 0.7-0.9). Prior chemother- 
apy was not associated with the development of sepsis 
(P = 0.96). 
Variables significantly associated with survival are 
shown in Table 3. Significant predictors of improved sur- 
vival included less severe neutropenia (for each increase 
in nadir ANC by 100 cells/pL, adjusted OR = 1.3; 95% CI 
= 1. l-l .7; P = 0.03) and CSF use (adjusted OR = 4.2; 95% 
CI = 1.2- 14.6; P = 0.02). Length of stay (for every increase 
in length of stay by 5 d, adjusted OR = 0.8; 95% 
CI = 0.6-0.9; P = 0.001) and sepsis (adjusted OR = 0.1; 
95% CI = 0.02-0.2; P < 0.001) were associated with 
poorer survival to discharge. There was a trend toward 
CD4+ cell counts being associated with improved sur- 
vival (for every increase in CD4+ cell count by 50, 
adjusted OR = 1.6; 95% CI = 0.9-2.8; P = 0.07). 
DISCUSSION 
The rationale for the use of CSFs lies in their potential to 
reduce the duration and severity of neutropenia, both of 
which have been related to the frequency and severity 
of infectious complications in cancer patients. Whereas 
the use of G-CSF or GM-CSF has been studied in 
chemotherapy-induced neutropenia,10-15 their use in HIV 
disease is less well characterized. 
The authors found CSF use, along with less severe 
neutropenia (i.e., higher nadir ANC), to be independently 
associated with improved survival to discharge in this 
patient population. To the authors’ knowledge, this is the 
first evidence that CSF use improves survival in hospi- 
talized, neutropenic HIV-infected patients. This effect was 
not clearly related to reduced duration of neutropenia, 
length of stay, or infectious complications, although the 
power to detect such effects may be limited, owing to the 
available sample size. The survival benefit was greater in 
those with nadir ANCs between 25 1 and 500 cells/FL, in 
whom prolonged periods with ANC below 500 cells/pL 
was associated with greater rates of sepsis. Survival to 
discharge was also higher among septic patients who 
received CSFs (63% vs. 38%) although this did not reach 
statistical significance (.P = 0.075). Together, these findings 
suggest that CSF use may reduce the clinical severity of 
infectious complications in these situations. 
Table 3. Logistic Regression Model for Survival to Discharge 
Factor Adjusted OR 95% Cl Significance (P) 
CSF use 4.2 1.20-14.60 0.0260 
Nadir ANC* 1.3 1.10- 1.70 0.0340 
Duration of hospitalization+ 0.8 0.60- 0.90 <0.0010 
CD4+ count’ 1.6 0.90- 2.80 0.0741 
Sepsis 0.1 0.02- 0.20 <0.0010 
*Each increase in nadir ANC by 100 cells/wL; teach increase in length of stay 
by 5 days; *each increase in CD4+ cell count by 50 cells/FL. 
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Patients receiving CSFs had significantly more site- 
related infections and prolonged durations of neutrope- 
nia, but these differences did not persist when patients 
in whom CSF administration was delayed by 1 or more 
neutropenic days were excluded, suggesting that CSF 
administration may have been prompted by suspicion of 
infection. However, CSF use also was associated inde- 
pendently with an increased rate of development of bac- 
teremia, even after exclusion of patients with catheter- 
related infections or delayed CSF administration. The rea- 
son for this association is uncertain. Neither the duration 
of neutropenia nor nadir ANC were associated with bac- 
teremia. Previous reports have suggested that CSFs admin- 
istered prior to the onset of severe neutropenia may 
reduce the development of bacteremia.z2az5 This suggests 
that the timing of CSF administration may influence the 
risk of bacteremia. The present study is not directly com- 
parable because CSF use was driven by clinical events. In 
this retrospective study, the authors could not rigorously 
ascertain the extent to which CSF administration was 
prompted by the degree of neutropenia, clinical symp- 
toms (such as fever, sepsis, or bacteremia), or both. To 
the extent that CSF use was driven by clinical events, it 
may have reduced the sequelae of such infections rather 
than the rate per se. Although patients with bacteremia 
might be expected to have poorer outcomes, bacteremia 
was not associated independently with lower survival 
rates in this study; likewise, Keiser et al found no relation 
between survival and prevention of bacteremia in neu- 
tropenic HIV-infected patients treated with G-CSEz2 This 
may account for the improved survival in CSF treated- 
patients despite their higher rate of bacteremia. 
There are several limitations to these data. One poten- 
tial limitation is that some patients with HIV-related neu- 
tropenia might not have been identified by the process 
of surveying discharge diagnostic codes. However, this 
would seem unlikely, because neutropenia appears to 
have been overcoded rather than undercoded on dis- 
charge (of 640 admissions, 242 had an ANC <lOOO 
cells/pL). There was variability in the CSF dosing regi- 
mens prescribed. However, this likely would lessen any 
observed effect. Further, variability in CSF dosing had no 
significant effects on any outcomes. In this retrospective 
study, the authors could not rigorously ascertain reasons 
for delayed initiation of CSF therapy Delays in CSF admin- 
istration could affect comparisons of duration of neu- 
tropenia and lengths of stay, but there were no differences 
even when such patients were excluded. Finally, patients 
who received CSFs seemed to have more advanced HIV 
disease, as evidenced by their lower CD4+ cell counts 
and nadir ANCs, and greater frequency of admission. This 
also likely would lessen any observed benefit in survival. 
In conclusion, G-CSF or GM-CSF use appears to 
improve survival in hospitalized HIV-infected patients 
with neutropenia. This effect was most marked in patients 
with sepsis or with ANCs below 500 cells/FL. Future 
study should focus on discerning the optimal timing of 
CSF administration, appropriate patient selection, and the 
effects of CSFs on long-term survival. 
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